Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05647252
Other study ID # Prov. Wissenschaftsantrag 980
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date February 27, 2023
Est. completion date April 30, 2025

Study information

Verified date August 2023
Source Balgrist University Hospital
Contact Ilker Uçkay, Prof.
Phone +41443863705
Email ilker.uckay@balgrist.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The general decolonization of the human body surface by industrial antiseptic agents, before elective surgery is recommended by the World Health Organization (WHO). A specific randomized-controlled trial specifically among high-risk adult orthopedic patients for infection has not been performed. In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision surgery and surgical site infections


Description:

The general decolonization of the human body surface and, of adjacent pathogen reservoirs such as the nose, by industrial antiseptic agents by the World Health Organization (WHO) for the risk reduction of superficial and deep surgical site infection (SSI). Such a decolonization is regarded as evidence-based in the majority of randomized, and before-after trials, since two decades, although negative studies also exist. In the orthopedic field, this decolonization is likely to be more effective in elective patients with a proven body colonization of Staphylococcus aureus. The decolonization might be equally efeective in orthopedic patients with an inherent high risk for SSI, for which the majority of future SSI pathogens are skin commensals and S. aureus. These (eventual and future) pathogens of SSI are accessible to the topical agents during the index surgery, if the patients are well instructed and know how to decolonize themselves. In contrast, this pre-surgical decolonization is only a supplementary measure in the bundle of all combined efforts to prevent revision surgery for infection. Its individual power is limited for young, healthy individuals, for SSIs caused by pathogens from the internal body sites (intestinal, urinary, gynecologic regions), infections acquired on the surgical ward, and in settings with less specialized surgeries and a low volume of surgical experience. Hence, in trials including all patients (or only those carrying S. aureus), the beneficial effect of decolonization can be diluted and provoke an additional costly and cumber-some organizational procedure for the majority of patients with low to moderate SSI risks. Moreover, many surgical site infections in orthopedic surgery, especially in implant-related surgery, are more due to coagulase-negative staphylococci (CoNS) than for S. aureus. The hallmark of the CoNS group is S. epidermidis with approximatively 70% resistance (in Switzerland) to standard prophylactic antibiotic agents9, As S. epidermidis is part of the normal human flora, typically the skin flora, and, only becomes pathogenic under certain conditions, a screening for this microorganism is not feasible in common practice,. while the prophylaxis-resistant part of all orthopedic SSI pathogens is at 30-50%. In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision sur-gery and SSI; inde-pendently of a known body carriage for S. aureus. This study will be performed with an existing "set" manufactured by Schülke & Mayr GmbH. The "Set" was placed on the market in 2016. The distribution of Octenisan® wash lotion and Octenisan® nasal gel in the form of a set (Octenisan® Set) largely streamlines and facilitates the organizational application and compliance efforts of the study. Academically and clinically, we will gain insight in the performance of decolonization for a patient population at particular risk of postoperative complications, where every effort to prevent infection is of importance.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date April 30, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Patients with an age = 80 years (as considered particularly at risk for SSI) - Elective orthopedic surgery at the Balgrist - Chronic immune-suppression (diabetes mellitus, active cancer, cirrhosis CHILD C, renal dialysis, untreated HIV disease, medicamentous immune-suppression equivalent to prednisone = 10 mg/day) - Elective surgery in ischemic skin (e.g. major amputations) - Elective surgery on non-diabetic and non-infected ulcerated skin - Tumor (oncologic) orthopedic surgery - ASA-Scores 3-4 points Exclusion Criteria: - Elective revision orthopedic surgery due to orthopedic infection within the last 12 months in the same area of surgery - Emergency surgery (defined as planned surgery within the next 48 hours) - Surgery on infected skin; or surgery under antibiotic treatment for any reason - "Diabetic foot surgery" (distinct clinical entity; defined as below the ankle) - Body mass index = 35 kg/m2 (anticipated difficulty of effective decolonization) - Pregnancy (formality reasons) - Intolerance or allergy to octenidin and/or ingredients in the Octenisan® set - Use of any other topical antiseptic agents other than Octenisan® set (except for the duration of one day) - Patient unable to understand; or under legal guardian for medical decisions - Anticipated clinical follow-up of less than 6 weeks after surgery. - ASA-Scores 1-2, and ASA-Score 5 (high risk of postoperative complications) - Known skin colonization with antibiotic-multiresistant Gram-negative organisms defined by infection control protocols of Switzerland1

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Whole Body and nasal decolonization with octenidin (Octenisan Set)
Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair. Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period
Behavioral:
Questionnaire for study participants immediately after the decolonization
A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case). The questionnaire is handmade and validated by the Investigators.

Locations

Country Name City State
Switzerland Balgrist University Hospital Zürich Zurich
Switzerland Balgrist University Hospital Zürich

Sponsors (2)

Lead Sponsor Collaborator
Balgrist University Hospital Industry (Schülke & Mayr AG, Switzerland and Germany)

Country where clinical trial is conducted

Switzerland, 

References & Publications (5)

Dancer SJ, Christison F, Eslami A, Gregori A, Miller R, Perisamy K, Robertson C, Graves N. Is it worth screening elective orthopaedic patients for carriage of Staphylococcus aureus? A part-retrospective case-control study in a Scottish hospital. BMJ Open. — View Citation

Prentice HA, Chan PH, Champsi JH, Clutter DS, Maletis GB, Mohan V, Namba RS, Reddy NC, Hinman AD, Fang AS, Yian E, Navarro RA, Norheim EP, Paxton EW. Temporal Trends in Deep Surgical Site Infections After Six Orthopaedic Procedures Over a 12-year Period W — View Citation

Rohrer F, Notzli H, Risch L, Bodmer T, Cottagnoud P, Hermann T, Limacher A, Fankhauser N, Wagner K, Brugger J. Does Preoperative Decolonization Reduce Surgical Site Infections in Elective Orthopaedic Surgery? A Prospective Randomized Controlled Trial. Cli — View Citation

Tsang STJ, McHugh MP, Guerendiain D, Gwynne P, Boyd J, Laurenson IF, Templeton KE, Lewis S, Simpson AHRW, Walsh TS. Evaluation of Staphylococcus aureus eradication therapy in orthopaedic surgery. J Med Microbiol. 2018 Jun;67(6):893-901. doi: 10.1099/jmm.0 — View Citation

Uckay I, Hoffmeyer P, Lew D, Pittet D. Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. J Hosp Infect. 2013 May;84(1):5-12. doi: 10.1016/j.jhin.2012.12.014. Epub 2013 Feb 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Remission (and inversely surgical site infection) Remission is defined as the absence of clinical, anamnestic, radiologic or laboratory signs of infection. At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Primary Wound problems after elective surgery Wound problems (dehiscence, seroma, hematoma, necrosis) occurring after surgery Until week 6 after surgery
Secondary Unplanned revision surgery for non-infection problems in same time period Any revision in the operating theatre due to non-infectious pathologies At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Secondary Adverse events All adverse events during the decolonization and hospitalization periods At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Secondary Subjective opinion and information on the decolonization Questionnaire with 5 questions only for patients being decolonized A day within one week after surgery (during the hospitalization)
See also
  Status Clinical Trial Phase
Completed NCT04361799 - Perioperative Closed-loop Glucose Control N/A
Completed NCT01193972 - Decision Aid Development for Smokers Phase 1
Completed NCT02932397 - Efficacy of Propofol vs Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane N/A
Completed NCT00795392 - Preoperative Psychological Evaluation as Predictor of Outcomes N/A
Completed NCT00966186 - The Rotational Insertion Technique for ProSeal Laryngeal Mask Airway N/A
Completed NCT01856998 - Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery Phase 3
Not yet recruiting NCT06344325 - ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia Phase 4
Completed NCT03857750 - Neuromuscular Blocking Agents in the Elderly
Completed NCT00875134 - Testing of the Apnea Prevention Device Phase 1/Phase 2
Completed NCT00290108 - The Influence of Injection Rate on EEG Propofol Peak Effect as Measured by Bispectral Index N/A
Completed NCT04020887 - Telemedicine Control Tower for the Post-Anesthesia Care Unit N/A
Not yet recruiting NCT06039306 - Perioperative Immunonutrition Under Enhanced Recovery After Surgery N/A
Completed NCT00948597 - Development of PK/PD Model for Individualized Propofol Dosing N/A
Completed NCT00776880 - Does American Society of Anesthesiologists (ASA) Physical Status Scale Enough in Patients Assessment N/A
Completed NCT04089592 - Comparison Of Dexmedetomidine and Fentanyl In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy. N/A
Not yet recruiting NCT03593252 - Bowel Preparation in Elective Pediatric Colorectal Surgery N/A
Not yet recruiting NCT04225702 - Effect Of Aspirin Preoperative on Postoperative Cognitive Dysfunction In Elderly Patients Undergoing Knee Arthroplasty
Completed NCT00205244 - Preoperative Preparation for Children N/A
Completed NCT05392452 - Fully Closed-Loop Insulin Delivery in Abdominal Surgery (CLAB) N/A
Completed NCT03455413 - Quality of Perioperative Invasive Ventilation in PICU